Clin Mol Hepatol.  2016 Dec;22(4):499-502. 10.3350/cmh.2016.0016.

Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban

Affiliations
  • 1Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea. mjsong95@gmail.com

Abstract

Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban.

Keyword

Liver cirrhosis; Portal vein thrombosis; Rivaroxaban

MeSH Terms

Administration, Oral
Factor Xa Inhibitors/*therapeutic use
Female
Humans
Liver Cirrhosis/*complications/diagnosis
Middle Aged
Portal Vein
Recurrence
Rivaroxaban/*therapeutic use
Tomography, X-Ray Computed
Venous Thrombosis/complications/diagnostic imaging/*drug therapy
Factor Xa Inhibitors
Rivaroxaban
Full Text Links
  • CMH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr